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In March 2004 a group of 65 physicians and other health pro-
fessionals representing nine countries on four continents con-
vened in Israel to discuss the widespread public health crisis
in childhood obesity. Their aim was to explore the available
evidence and develop a consensus on the way forward.
The process was rigorous, although time and resources did
not permit the development of formal evidence-based guide-
lines. In the months before meeting, participants were allo-
cated to seven groups covering prevalence, causes, risks, pre-
vention, diagnosis, treatment, and psychology. Through
electronic communication each group selected the key issues
for their area, searched the literature, and developed a draft
document. Over the 3-d meeting, these papers were debated
and finalized by each group before presenting to the full group
for further discussion and agreement.
In developing a consensus statement, this international
group has presented the evidence, developed recommenda-
tions, and provided a platform aimed toward future corrective
action and ongoing debate in the international community.
(J Clin Endocrinol Metab 90: 1871–1887, 2005)
Prevalence
What is the scope of the problem?
There has been a worldwide increase in obesity among
people of all ages. The definition of obesity varies but is
based on body mass index (BMI) cutoffs described below.
As many as 250 million people, or about 7% of the current
world population, are obese. Two to three times more
people are overweight. In one of the most extreme exam-
ples, the prevalence of overweight doubled among chil-
dren 6 –11 yr of age and tripled among those 12–17 yr of
age in the United States between the second National
Health and Nutrition Examination Survey, conducted be-
tween 1976 and 1980, and the most recent such survey,
conducted in 1999 and 2000. Approximately 14 –15% of all
15 yr olds in the United States can be classified as obese
(1). African-Americans, Hispanics (predominantly Mexi-
can and Puerto Rican), Pima Indians, and other Native
Americans have a particularly high predisposition to obe-
sity. There are national differences in prevalence rates for
obesity (2). Comparison of cross-sectional data from
school-based surveys conducted in 1997 and 1998 describ-
ing body size among adolescents in 13 European countries,
Israel, and the United States showed that the United States,
Ireland, Greece, and Portugal had the highest prevalence
of overweight (Table 1) (3). A review of 21 surveys con-
ducted in various European countries indicated a higher
prevalence of overweight in western and southern Europe.
The countries surrounding the Mediterranean showed
prevalence rates for overweight children in the range of
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20 – 40%, whereas those in northern areas showed lower
rates, in the range of 10 –20% (4).
Evaluation of Australian children from surveys taken 10 yr
apart also showed an increase of overweight and obesity. By
1995 15% of boys and 15.8% of girls were overweight, and
4.5% of boys and 5.3% of girls were classified as obese (5). In
other Asian populations, Polynesians, Micronesians, An-
urans, and Maoris are at high risk for obesity.
There has also been a trend toward increasing prevalence
of overweight and obesity as well as metabolic complications
in developing countries. Regions with the highest prevalence
of overweight were: the Middle East, 7%; North Africa, 8%;
and Latin America and the Caribbean, 4.5–7% (6).
Overweight children often become overweight adoles-
cents and adults (7), and overweight in adulthood is a serious
health risk (8). Obesity is associated with the development of
a number of serious medical complications and increased
mortality in children and adults. Thus, monitoring trends in
the prevalence of obesity in populations worldwide is im-
portant for epidemiological assessment.
Why is obesity so prevalent?
Man has evolved under conditions of stress in which it was
advantageous to be able to store fat (9). It is this genetic
propensity to store fat in response to insulin, paired with our
lifestyles with too much sedentary activity and processed
energy-dense foods, that has contributed to the problem of
overweight. Numerous genetic markers have been linked
with obesity and its metabolic consequences (10), yet iden-
tifiable hormonal, syndromic, or molecular genetic abnor-
malities can presently account for less than 5% of obese
individuals (11). This is discussed in greater detail in Causes.
Diagnosis
Clinical evaluation: How do we evaluate overweight and
obesity in childhood?
Basic evaluation: history and anthropometrics. The definition
of overweight and obesity in childhood is still a matter of
debate for two main reasons: the lack of a simple, low-cost,
accurate, and reproducible method to measure fat mass in
infants, children, or adolescents and the lack of cutoffs of fat
mass for children to identify individuals at moderate or high
cardiovascular and metabolic risk in childhood and adult-
hood. Whitaker et al. (12) demonstrated that the prognostic
importance of obesity in infancy and childhood depends on
the presence or absence of obesity in one or both parents.
It is important to distinguish between primary or idiopathic
obesity and the rarer situation of secondary obesity owing to
genetic disorders, endocrine disease, central nervous system
lesions, or iatrogenic causes. Detailed medical history, physical
examination, and laboratory tests are helpful.
In the initial assessment of the overweight or obese child,
nutritional history should include breast-feeding or formula;
age at introducing solids; and assessment of caloric intake,
including dietary quality in terms of the balance of nutrients
and food groups. The clinician should ask about the child’s
level of physical activity; limitations due to weight; and
respiratory difficulties including snoring and somnolence,
potential signs of sleep apnea.
Physical examination should first be directed to overall
body proportions and the presence or absence of any dis-
tinctive or dysmorphic features that could guide the diag-
nosis to rare obesity syndromes. Recording and graphical
plotting of height, weight, BMI, and waist circumference
should be done at each visit.
Quantitation of body fat in childhood and adolescence. Over-
weight and obesity occur with excessive accumulation of
body fat. Because increasing body fat is associated with in-
creasing morbidity, the definition of overweight and obesity
should be linked to health risks. Due to difficulties in direct
measurement of body fat, obesity can be simply and inex-
pensively estimated using the BMI. BMI correlates with the
amount of body fat in both children and adults (13). The
World Health Organization (WHO) classification and U.S.
dietary guidelines for obesity in adults define overweight
based on health risk as a BMI of 25–30 kg/m2 and obesity as
a BMI of 30 kg/m2 or greater.
Country-specific growth charts have been developed based
on cross-sectional and longitudinal data. For example, the U.S.
Centers for Disease Control and Prevention (CDC) 2000 growth
charts include gender-specific BMI for age growth charts for
ages 2–19 yr (14). These charts were developed from five na-
tional data sets in the United States. Overweight and obesity
among individuals 2–19 yr old are defined as the 95th percentile
or greater of BMI for age; those with BMI between the 85th and
95th percentiles are considered at risk for overweight. In a
separate report from the National Heart, Lung, and Blood In-
stitute, overweight is defined in adolescents as the 85th per-
centile or greater of BMI for age (15). A recent review concluded
that the evidence for use of national BMI reference data is
sufficiently strong for its adoption in clinical practice and
screening (16). An advantage of these charts is that a child can
be followed up over time with graphical plotting of serial BMI
measures. A disadvantage is that the charts are based on ar-
bitrary statistical measures and not on biological data related to
the risk of later morbidity. Moreover, the CDC reference data
are based on American children and may not be applicable to
other populations. Another problem with this approach is that
TABLE 1. Prevalence of BMI 85th and 95th percentiles of
adolescents 15 yr of age by gender
Country
Boys (%) Girls (%)
85th 95th 85th 95th
Austria 11.6 5.1 10.9 4.4
Belgium 13.1 5.2 15.4 5.8
Czech Republic 8.1 1.9 9.3 3.5
Denmark 10.4 3.2 18.2 6.5
Finland 15.6 4.9 14.5 5.1
France 9.8 2.7 12.8 4
Germany 14.2 5.4 14.8 5.1
Greece 28.9 10.8 16.4 5.5
Ireland 19.3 2.8 14.2 4.7
Israel 20.1 6.8 16.4 6.2
Lithuania 5.2 0.8 8.1 2.1
Portugal 14.3 5.2 20.8 6.7
Slovakia 16.5 4.4 11.3 1.1
Sweden 12.3 4 12.3 3.4
United States 28.2 13.9 31 15.1
Total 15 5.3 15.3 5.5
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as the population becomes heavier, these percentiles define
changing thresholds for overweight and obesity.
To have an absolute and internationally relevant definition
of child overweight and obesity, Cole et al. (2) developed age-
and sex-specific cutoff lines from data derived from six coun-
tries across several continents using BMI. These charts ex-
trapolate risk from the adult experience to children. The
International Obesity Task Force (IOTF) has recommended
this approach for the comparison of populations (17). IOTF
currently defines overweight as approximately 91% or
greater and obesity as approximately 99% or greater. The
charts of Cole et al. are recommended for epidemiologic
purposes and may underestimate the prevalence of obesity
if applied to cross-sectional charts. Owing to the lack of
precise percentiles, these charts are not useful for longitu-
dinal follow-up of individual patients.
Quantitation of body fat in infancy. Weight for length is
usually used in the under 2-yr age group. In the United
States, overweight in this age group is defined as greater than
the 95th percentile of the weight for length. The definition is
purely statistical, and the percentile values are age and gen-
der specific. It is important to measure head circumference
because a very large head may alter weight-for-length ratio.
Laboratory tests for body fat
What are the most reliable methods of assessment of body fat and
its distribution? As discussed, BMI, an indirect estimate of
total adiposity, does not necessarily predict health risk for
children. There are some situations in which BMI gives an
inaccurate picture, e.g. in short muscular people. Further-
more, BMI does not distinguish between sc and visceral fat.
It is therefore useful to employ adjunctive measures of total
and regional body fat.
Skinfold thickness. This is a quick, simple, inexpensive
method, which is useful for community pediatrics and large
studies and gives information on fat distribution because it
is done at several body sites. It does not require a high degree
of technical skill, although the technique requires a trained
person to standardize the measurements; otherwise it is
poorly reproducible, especially at the highest BMIs. Triceps
skinfold is correlated with fat mass and, combined with BMI,
increases the sensitivity for the determination of percent
body fat (18).
Bioelectric impedance assay (BIA). BIA is a method of body
composition assessment that is simple, quick, relatively in-
expensive, and noninvasive. However, BIA measurements
are highly variable because they are affected by meals; phys-
ical activity; and other variables that change the subject’s
hydration state, such as menstrual phase, acute illness, kid-
ney disease, and water and electrolyte disturbances (19).
Hydrodensitometry. Underwater weighing requires special
equipment and is used primarily for research purposes; it is
not available for routine clinical care. It is useful for valida-
tion of other methods of measuring body fat.
Dual-energy x-ray absorptiometry (DEXA). This is a rela-
tively expensive but safe method for assessing total body fat
that has high precision and simplicity for the subject. X-ray
exposure is minimal. DEXA also is limited by the inability to
distinguish between sc and visceral fat. The method is most
useful for research.
Imaging. Computed tomography and magnetic resonance
imaging of the abdomen are accurate methods that can be
used to measure visceral fat (20). However, the disadvan-
tages are high cost and radiation exposure with computed
tomography. These methods require more time to perform
and specialists for interpretation. Therefore, these methods
are also recommended only for research purposes.
Anthropometrics. Waist circumference or waist to hip ratios
are used as indirect markers of intraabdominal adipose tis-
sue. As with BMI, there is some controversy as to appropriate
cutoffs for adults. Waist circumferences above 95 cm indicate
elevated mortality rates (21). This parameter is also a pre-
dictor of cardiovascular and metabolic risk factors in obese
children (22). Visceral or intraabdominal adiposity is also
associated with the metabolic syndrome (see definitions in
Risks) in adults and children. Methodologies such as DEXA,
skinfolds, and BIA do not assess visceral fat. Thus, waist
circumference should be included in clinical practice as the
least invasive and least costly tool to help identify obese
children at higher metabolic risk. Currently there are limited
pediatric reference values for waist circumference (24, 25),
and these should be developed.
Causes
Genetic: which genes are important determinants of obesity?
Monogenic obesity. Leptin was the first specific gene recog-
nized as important in human body weight control. This adi-
pocyte hormone is involved in a complex circuit of hormones
and neurotransmitters to control appetite (Table 2). To date,
several monogenic obesity syndromes have been identified,
and most involve the leptin-melanocortin regulation path-
way (26, 27). The known genes include leptin, the leptin
receptor proopiomelanocortin (POMC), prohormone con-
vertase 1, melanocortin receptors 3 and 4, and the transcrip-
tion factor single-minded 1; the list will continue to expand.
Severe and early-onset obesity, common findings in mono-
genic cases, parallels the phenotype in the corresponding
knockout mice and supports the central role of these genes
in body weight regulation. There have been conflicting re-
ports about the association between obesity and human poly-
morphisms in genes involved in the regulation of peripheral
metabolic control, e.g. mitochondrial uncoupling genes, per-
haps attributable to ethnic or gender-specific variations (28).
Homozygous mutations of the leptin-melanocortin genes
are extremely rare causes of severe obesity and are often
associated with other features, e.g. hypogonadotropic hypo-
gonadism in leptin deficiency (26) and red hair and hypo-
cortisolism in POMC deficiency (29) resulting in phenotypes
that exclude these genes as likely candidates for common
obesity. In the case of leptin, leptin receptor, and POMC
genes, heterozygous mutation carriers have a minimally ab-
normal phenotype. Heterozygous mutations causing signif-
icant obesity are found only in the melanocortin receptor
(MCR) 4 and are not associated with an otherwise distinctive
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phenotype. To date, MC4R mutations are the most frequent
known cause of monogenic human obesity, occurring in up
to 4% of early-onset and severe childhood obesity (30).
Other candidate genes involved in human obesity. Because in-
sulin plays a crucial role in energy metabolism, the insulin
gene has been examined. There is an association between
variable nucleotide tandem repeat polymorphisms upstream
of the insulin gene, increased fasting insulin levels, and child-
hood obesity in individuals of European descent (31).
The human obesity gene map continues to expand as more
genes and chromosomal regions are linked with human obe-
sity. In the most recent published update, there were more
than 430 genes, markers, and chromosomal regions associ-
ated or linked with human obesity phenotypes. There are 35
genomic regions with quantitative trait loci that have been
replicated in two or more studies of obesity phenotypes (32).
Every chromosome, except the Y chromosome, has had loci
linked with the phenotype of obesity. Some genes have been
identified that are specific to visceral obesity. Most of the
specific genes involved are as yet unknown. In view of these
data, it is highly probable that childhood obesity is polygenic
with susceptibility conferred via complex genetic factors. It
is estimated that 30–50% of the tendency toward excess ad-
iposity can be explained by genetic variations (33).
Which syndromes are associated with early childhood obesity?
Obesity is a component of several rare human genetic
syndromes that present with characteristic phenotypes; two
of these are described here. Prader-Willi syndrome (PWS;
OMIM no. 176270) is characterized by intrauterine hypoto-
nia, mental retardation, and hypogonadotropic hypogonad-
ism. The obesity of PWS that occurs in early childhood is
resistant to diet and associated with early mortality. PWS is
caused by the loss of paternally expressed genes, including
small nuclear ribonucleoprotein, within the PWS critical re-
gion on chromosome 15q; however, the precise metabolic
functions of the missing gene products remain unknown.
One major difference in the obesity associated with PWS is
the presence of elevated ghrelin levels contrasting with de-
creased levels in other forms of obesity. Ghrelin, an orexi-
genic protein, may be responsible, at least in part, for the
hyperphagia observed in PWS (34).
Bardet-Biedl syndrome (BBS; OMIM no. 209900) is char-
acterized by a variable degree of obesity; mental retardation;
and pigmentary retinopathy, polydactyly, and renal abnor-
malities (35). Based on several large pedigrees with mainly
recessive inheritance of the BBS phenotype, several chromo-
somal regions, including genes involved in cilial and cent-
riole function, have been identified (36).
Beckwith-Wiedemann syndrome (BWS; OMIM no. 130650)
is principally characterized as a syndrome of generalized fetal
overgrowth and visceromegaly with tall stature but not
specifically obesity in childhood.
Endocrine: are endocrine disorders a common cause of
obesity?
Although rare among children and adolescents with obe-
sity, GH deficiency, thyroid hormone deficiency, and cortisol
excess are characterized by a combination of decreased en-
ergy expenditure and decreased growth resulting in prom-
inent central adiposity in a short, slowly growing child. GH
therapy in individuals with GH or IGF-I deficiency reverses
these changes in body composition, reducing fat mass while
increasing muscle mass (37). Thyroid hormone replacement
increases resting metabolic rate and improves impaired se-
cretion of GH and IGF-I production that accompany thyroid
hormone deficiency. Patients with excessive cortisol levels
often have hypertension, glucose intolerance, dyslipidemia,
moon facies, decreased muscle mass, and broad violaceous
striae in addition to visceral obesity and poor growth. Re-
moving the glucocorticoid source ameliorates these prob-
lems (38). Insulin and leptin are produced in the periphery,
circulate at levels proportional to body fat content, and enter
the central nervous system in proportion to their plasma
level. Receptors for leptin and insulin are expressed in brain
TABLE 2. Factors critical in the regulation of appetite and energy balance
Central nervous system-appetite regulation command: Ventro-medial-hypothalamus, paraventricular nucleus, lateral hypothalamus area








Opioids (-endorphin, dynorphin, met-enkephalin)
Orexins, hypocretins
Cocaine and amphetamine reg. transcript (CART)
Corticotropin-releasing hormone (CRH)
Dopamine






Central nervous system outgoing signals
Suppressing Stimulating
Amylin Cortisol Parasympathetic nervous system: vagus nerve
Bombesin Ghrelin Energy storage by glucose-stimulated insulin secretion
GLP1 Glucose (low) Sympathetic nervous system: -adrenergic activation
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neurons involved in regulating energy intake; administra-
tion of either peptide directly into the brain induces satiety
(39). Hyperinsulinism, relative insulin resistance, and to a
lesser extent type 2 diabetes mellitus (T2DM) are recognized
comorbidities of obesity in the young (40). Insulinomas are
rarely diagnosed in children. With hyperinsulinism and nor-
mal insulin sensitivity, symptoms of hypoglycemia would
herald the diagnosis before the onset of obesity in most cases.
Most obese individuals have elevated circulating insulin and
leptin levels and are relatively resistant to the satiety-induc-
ing effects of both hormones.
Pseudohypoparathyroidism is a rare cause of childhood
obesity, also associated with PTH resistance with hypocal-
cemia and hyperphosphatemia, short stature, round face,
short metacarpals, basal ganglia calcification, and develop-
mental delay.
Laboratory investigations directed at identifying comor-
bidities of obesity may include thyroid functions, lipid pro-
file, complete chemistries and hepatic profile, and fasting
glucose and insulin. An oral glucose tolerance test (OGTT)
should be considered to exclude impaired glucose tolerance
or T2DM in individuals at high risk, e.g. family history of
T2DM and/or metabolic syndrome, after 10 yr of age. De-
termination of serum or urinary cortisol levels should be
reserved to exclude the presence of Cushing’s syndrome in
obese individuals who have appropriate historical informa-
tion and/or physical findings.
Infants who are hypoglycemic or require very frequent feed-
ings as well as infants with dysmorphic features require further
evaluation. Examples include persistent hyperinsulinemic hy-
poglycemia of infancy (OMIM no. 601820) and BWS with hy-
poglycemia, or PWS and BBS with dysmorphism.
Neurologic: how can central nervous system lesions
cause obesity?
Obesity is a frequent complication in children surviving
serious brain injury, brain tumors, and/or cranial irradiation.
Significant increases in weight are noted to occur in the early
postoperative period. These children often have reduced
physical activity more than increased energy intake. The
pattern of decreased physical activity may be secondary to
suboptimal hormonal replacement and decreased sympa-
thetic nervous system function. The exact mechanisms re-
sponsible for this phenomenon are still unknown, although
alterations in hypothalamic neuropeptides (41) and en-
hanced activity of 11- hydroxysteroid dehydrogenase, con-
verting cortisone to cortisol (42), have been implicated. These
individuals often have autonomic dysregulation of the -cell,
with insulin hypersecretion in response to oral glucose tol-
erance testing (41).
Medications: do medications cause obesity?
High-dose, chronic glucocorticoid treatment is well
known to be associated with a distinctive pattern of centrip-
etal weight gain with visceral fat accumulation predisposing
to cardiovascular risk. Other drugs used in children and
adolescents that may predispose to weight gain include
cyproheptadine, valproate, and progestins.
There is considerable evidence that treatment with some
newer antipsychotic drugs can cause a rapid increase in body
weight. There is, however, considerable variability among
the various drugs in their effect on weight gain, lipid profile,
and risk of diabetes. The prevalence of both diabetes and
hyperlipidemia among individuals with schizophrenia and
affective disorders is 1.5–2 times higher than the general
population (43). Among the second-generation drugs, which
have generally replaced first generation, clozapine and olan-
zapine, have a marked effect on weight gain, with increased
risks for developing diabetes and hyperlipidemia. Risperi-
done and quetiapine have a moderate effect on weight gain
and possible effects on development of diabetes and hyper-
lipidemia. Aripiprazole and ziprasidone are associated with
less weight gain and better glucose: insulin and lipid profiles;
however, there is less long-term experience with the latter
drugs (44).
Environment: how does environment contribute to the
genetic predisposition to obesity?
Genes play a permissive role and interact with environ-
mental factors to promote obesity. Studies of energy balance
among pairs of monozygotic twins have shown that subjects
with the same genotype are more alike in response to energy
surplus and deprivation than are subjects with different ge-
notypes for changes in circulating lipid levels, sc fat, fat mass,
and visceral fat in response to dietary changes. Advances in
the ability to generate genotypic information, in combination
with precise phenotypic markers, will improve our capacity
to better determine gene-environment interactions (45).
Does the in utero milieu contribute to obesity? Epidemiological
studies of the impact of maternal gestational diabetes mel-
litus (GDM) on adolescent obesity demonstrate conflicting
results. Infants of Pima Indians with GDM had an increased
risk of obesity, compared with siblings born before their
mothers developed GDM. This study supports the role of in
utero exposure to hyperglycemia as a risk factor for subse-
quent obesity (36). Other studies (37, 38) demonstrated an
increased risk of adolescent overweight associated with in-
creased birth weight and maternal GDM, yet the association
was attenuated or lost completely after adjustment for ma-
ternal BMI. Thus, the effect of fetal hyperinsulinemia on body
composition and size at birth may set the stage for the future
development of obesity.
Psychosocial factors
What is the impact of socioeconomic status (SES), race, ethnicity,
and gender? Most of the data in this area are derived from the
adult population in the United States (46). In general, those
with lower income and education levels are more likely to
become obese than those with higher income levels and
higher education levels, who may have greater awareness of
and access to health care, healthy foods, and fitness facilities.
The prevalence of obesity is higher in racial and ethnic
minorities, perhaps attributable to greater poverty among
these groups. Selective weight gain in certain populations
may also indicate that the interaction between people and
their environment varies according to genetic background.
Clearly some populations are at greater risk of obesity-
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related morbidity. Therefore, effective prevention and treat-
ment may require racial and ethnic-specific strategies.
Gender influences the impact of SES and ethnicity on the
development of obesity in that a poor woman is twice as
likely to become obese as a poor man. Conversely, a wealthy
woman is less likely to become obese than a wealthy man.
However, a wealthy man is significantly more likely to be
overweight than a man with low SES. Overall, women are
more likely to be obese than men. In view of the influence of
maternal BMI on their children, this is especially concerning.
According to the American Obesity Association, among
women between the ages of 20 and 74 yr, 34% are obese
(BMI  30) and 6.3% are severely obese (BMI  40), com-
pared with 28 and 3.1%, respectively, for men (47).
What is the role of lifestyle and diet? Studies using motion
sensors have shown that children who spend less time in
moderately vigorous activity are at higher risk to become
obese during childhood and adolescence (48). In the United
States, only about 25% of adolescents report regular exercise,
and an alarming 14% say they do not exercise at all. Tele-
vision and video games have contributed to more sedentary
leisure activities as well as increased snacking and inappro-
priate food choices due to television advertising. There is a
positive correlation between hours of television viewing and
overweight, especially in older children and adolescents (49).
Aside from these lifestyle issues, eating patterns of chil-
dren and adolescents have changed dramatically in the past
few decades (50). Dietary factors that place children at risk
for obesity include high fat and excess calorie intake. Obese
children tend to skip breakfast but consume a large amount
of food at dinner (51).
In terms of dietary content, there is an inverse relationship
between calcium intake and adiposity (52). The consumption
of high-carbohydrate soft drinks is a major contributing fac-
tor to high calorie counts (53), especially because these fluids
tend to replace milk and calcium intake for adolescents.
Additionally, fast food consumption now accounts for 10%
of food intake in children in U.S. schools, compared with 2%
in the 1970s. Children who frequently eat fast food consume
more total energy, more energy per gram of food, more total
fat, more total carbohydrate, more added sugars, less fiber,
less milk (calcium), and fewer fruits and vegetables than
children who eat fast food infrequently (50, 54). Those who
are overweight are particularly vulnerable to the adverse
health effects of consuming fast foods (55).
It appears that neonatal nutrition has an impact on child-
hood and adolescent obesity. In particular, breast-feeding
has been shown to have at least some protective effect in
some populations (56, 57), although this has been refuted in
other reports (58).
Is binge eating a major cause of obesity? Twenty to 40% of
severely obese adults (59) and adolescents (60) suffer from
binge eating. Obese binge eaters show weight and shape
concern as well as symptoms of depression and anxiety with
lower self-esteem when compared with nonbingeing obese
individuals. Apparently binge eating disorder in youngsters
does not develop into bulimia nervosa in later life (61).
What is the psychological profile of obese children and adolescents?
A causal relationship between obesity and psychological fac-
tors remains unclear. Adiposity is very visible, and children
tend to rate disease and minor deformities as preferable to
obesity at 6 yr of age. Children’s perceptions of obesity em-
phasize laziness, selfishness, lower intelligence, social isola-
tion, poor social functioning, and academic success as well
as low levels of perceived health, healthy eating, and activity
(62). Thus, children share the overall negative societal per-
ceptions toward those who are overweight or obese. This is
regardless of the child’s own weight status or gender. Chil-
dren as young as 5 yr are aware of their own fatness, which
impacts their perceptions of appearance, athletic ability, so-
cial competence, and self-worth. Quality of life is poor among
obese youngsters by parental and self-report (63). Self-
esteem in obese children varies with gender and age. Females
are at greater risk for self-esteem problems (64). Parental
acceptance or lack of concern may be a protective factor for
self-esteem.
Among severely obese adolescents, 48% have moderate to
severe depressive symptoms and 35% report high levels of
anxiety. Obese girls are more likely to have attempted suicide
than nonobese girls. Overweight adolescents reported en-
gaging in significantly more unhealthy behaviors and expe-
riencing more psychosocial distress than their nonover-
weight peers. Overweight adolescents were found to be more
isolated and peripheral to social networks than were their
normal-weight peers (65).
Risks
Why is obesity of such concern?
Childhood obesity is now recognized as a major medical
and public health problem. Obesity in adults is strongly
associated with many serious medical complications that
impair quality of life and lead to increased morbidity. Obese
children are at high risk for adult obesity, but there are as yet
insufficient data to assign specific risk levels in childhood.
However, obesity in childhood provides an independent
contribution to the development of adult morbidity. Without
proper intervention, adult morbidities will likely begin to
appear in the young. There are strong epidemiologic and
causal links between obesity in the young and earlier-onset
T2DM (40).
Diabetes
Over the past decade, there has been an alarming increase
in the appearance of T2DM in children, a disease that for-
merly occurred almost exclusively in adults. T2DM in youth
represents the most rapidly growing form of diabetes in
America, Europe, Japan, and Australasia, now responsible
for up to about one fifth of new diagnoses of diabetes in
pubertal children. Although universal screening is not rec-
ommended, the American Academy of Pediatrics and Amer-
ican Diabetes Association recommend that all youngsters
who are overweight and have at least two other risk factors
should be tested for T2DM beginning at age 10 yr or at the
onset of puberty and every 2 yr thereafter (66). The risk
factors include family history of T2DM in first- or second-
degree relatives; belonging to certain ethnic groups (i.e. Na-
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tive American, African-American, Hispanic, Japanese, or
other Asian/Pacific Islander); or having signs associated
with insulin resistance (hypertension, dyslipidemia, acan-
thosis nigricans, or polycystic ovarian syndrome). Fasting
plasma glucose is the primary screen to test for T2DM in
young people. The 2-h blood glucose concentration after a
standard OGTT is more sensitive than plasma glucose in
assessing impaired glucose tolerance in youngsters, but it is
also more invasive, inconvenient, and expensive. Insulin re-
sistance is considered the greatest risk factor for the devel-
opment of T2DM. The homeostatic model assessment, which
estimates insulin resistance, and the quantitative insulin-
sensitivity check index, based on solely on fasting insulin and
glucose, provide a crude, and not always reproducible, mea-
sure of indices that are most accurately derived from the
more invasive euglycemic and hyperglycemic clamp studies
(67).
Metabolic syndrome (MS)
Metabolic changes seen in obese adults have been sum-
marized under the so-called MS. The MS is defined differ-
ently according to different authorities. The U.S. National
Cholesterol Education Program’s Adult Treatment Panel III
(68) requires three of five characteristics: 1) abdominal obe-
sity given as waist circumference greater than 102 cm in men
and greater than 88 cm in women; 2) hypertriglyceridemia
with triglyceride concentration (150 mg/dl or 1.7 mmol/
liter); 3) abnormal cholesterol profile with high-density li-
poprotein (HDL) cholesterol less than 40 mg/dl or 1 mmol/
liter in men and less than 50 mg/dl or 1.3 mmol/liter in
women; 4) blood pressure: 130/85 mm Hg or more; 5) im-
paired glucose tolerance, i.e. elevated fasting plasma glucose
100 mg/dl or 5.5 mmol/liter or more (69). The National
Cholesterol Education Program guidelines for adults have
been modified for adolescents such that triglycerides 110
mg/dl or 1.2 mmol/liter or more are considered abnormal,
and the HDL threshold is set at 40 or less. Waist circumfer-
ences 90% or more (from National Health and Nutrition
Examination Surveys III) are considered abnormal, as are
blood pressures 90% or more (70). There is as yet no defi-
nition of the MS for the pediatric age group, but using adult
criteria, the overall prevalence of MS among 12- to 19-yr-olds
in the United States was found to be 4.2% (70). Using mod-
ified criteria, Weiss et al. (71) found that the risk of MS was
nearly 50% in severely obese youngsters, and risk increased
with every 0.5-U increment in BMI.
The WHO (72) and American Association of Clinical En-
docrinologists (73) criteria overlap the above but differ by
requiring impaired fasting glucose, impaired glucose toler-
ance, or frank T2DM as defined on an OGTT. An added
diagnostic criterion of urinary albumin excretion rate greater
than 20 g/min has been included in the WHO/American
Association of Clinical Endocrinologists criteria.
Hyperandrogenism
In adolescent girls and young women, excess central or
abdominal body fat is associated with hyperandrogenemia
(74). Sex hormone-producing enzymes are expressed in ad-
ipose tissue, and up to 50% of circulating testosterone may
be derived from fat in young women (75). There is also a
causal relationship between high androgen activity and hy-
perinsulinemia in women. To complete the circle, insulin
resistance correlates strongly with the abdominal fat in obese
adolescent girls. Insulin resistance stimulates ovarian as well
as adrenal androgen and estrogen production. Obese females
also have lower concentrations of SHBG with consequent
further increase in the (free) biologically active fraction of the
sex hormones. These hormonal perturbations place the obese
adolescent girl at a high risk of menstrual disorders and early
onset of polycystic ovarian syndrome. Weight loss induces a
decrease in insulin resistance and androgenic activity, par-
ticularly in adolescent girls with the abdominal pattern (76).
Cardiovascular factors
Heart disease. Obesity produces a variety of cardiac structural
changes and hemodynamic alterations. Excessive adipose
accumulation induces increased blood volume and cardiac
output. Sleep apnea and obesity-related hypoventilation
may contribute to pulmonary arterial hypertension. In mor-
bid obesity these abnormalities may lead to a cardiomyop-
athy. Studies involving obese children and cardiovascular
risk are limited. The Bogalusa Heart Study indicated that
increased insulin and glucose levels in heavier children and
adolescents might be risk factors for increased left ventricular
mass corrected for growth (77). Childhood obesity does pre-
dispose to endothelial dysfunction, carotid intimal medial
thickening, and the development of early aortic and coronary
arterial fatty streaks and fibrous plaques (78). Whether child-
hood obesity, like adult obesity, increases the risks of myo-
cardial infarction, stroke, and certain malignancies is cur-
rently unproved.
Hypertension. Hypertension occurs more commonly in obese
persons at every age. Childhood obesity is the leading cause
of pediatric hypertension. Genetic, metabolic, and hormonal
factors such as insulin resistance, increased serum aldoste-
rone levels, salt sensitivity, and possibly elevated leptin lev-
els are linked to the hypertension of obesity. Systolic blood
pressure correlates positively with BMI, skinfold thickness,
and waist to hip ratio in children and adolescents (79).
Respiratory factors
Asthma and other respiratory problems. The association between
asthma and overweight or obesity is debatable. One possible
explanation for the apparent association between asthma
and obesity is that both asthma and obesity share coincident
increased prevalence. In obese people symptoms of breath-
lessness and wheezing may be due to the increased work of
breathing. Alternatively, obesity may have a direct effect on
the mechanical behavior of the respiratory system by altering
compliance or elastic recoil, resulting in reduced effective
lung volume, airway caliber, or respiratory muscle strength
(80).
Sleep disorders. There is a strong association between obesity
and obstructive sleep apnea (OSA) according to several co-
hort studies (81). Obese children are 4–6 times more likely
to have OSA, compared with lean subjects (82). OSA is di-
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agnosed by an overnight sleep study to measure the apnea-
hypopnea index (AHI). An AHI of 5/h or more establishes
the diagnosis of OSA. Weight reduction is the preferred
modality to minimize AHI. OSA in adults has been related
to the development of hypertension, cardiovascular diseases,
behavioral disorders, and poor quality of life (83).
Visceral factors
Nonalcoholic fatty liver disease. Obesity is associated with a
spectrum of liver abnormalities, referred to as nonalcoholic
fatty liver disease. Characteristic biochemical findings in-
clude 4- to 5-fold elevations in hepatic transaminases, and 2-
to 3-fold elevations in alkaline phosphatase and  glutamyl
transpeptidase. Bilirubin, albumin, and prothrombin may
rise in later stages. The natural history varies according to
histology: hepatic steatosis is frequently characterized by a
benign clinical course without histological progression; how-
ever, nonalcoholic steatohepatitis may become associated
with increasing fibrosis and eventual rare cirrhosis (84).
Most children and adults are relatively asymptomatic.
Some individuals may have right upper quadrant pain, ab-
dominal discomfort, weakness, fatigue, or malaise. Hepato-
megaly and stigmata of liver disease, such as palmar ery-
thema, vascular spiders, muscle wasting, jaundice, and
hepatic encephalopathy, may sometimes be present.
Gallbladder disease. Obesity, MS, and hyperinsulinemia, or
alternatively rapid and significant weight loss are important
risk factors for gallstone development (85). The mechanisms
involved are not entirely clear. Early recognition of the se-
verity of gall bladder disease is necessary for successful man-
agement. Thus, gall bladder disease should be considered in
the differential diagnosis of persistent abdominal pain in
obese adolescents.
Orthopedic factors
Overweight children are susceptible to developing bony
deformities that can predispose them to other orthopedic
problems later in life. Excess weight may cause injury to the
growth plate and result in slipped capital femoral epiphysis,
genu valga, tibia vara (Blount’s disease), flat kneecap pres-
sure/pain, flat foot, spondylolisthesis (low back pain), sco-
liosis, and osteoarthritis (86).
Dermatologic factors
Acanthosis nigricans, frequently found in young obese
individuals, is characterized by hyperpigmented, hyperker-
atotic, velvety plaques on the dorsal surface of the neck, in
the axillae, in body folds, and over joints. Severe skin changes
correlate with elevated serum insulin levels and can be ame-
liorated by weight loss and consequent reduction in insulin
resistance. Other skin problems commonly encountered in-
clude skin tags and keratosis pilaris (87).
Neurologic factors
Obesity is associated with idiopathic intracranial hyper-
tension, or pseudotumor cerebri, manifested by headache,
vision abnormalities, tinnitus, and sixth nerve paresis. Al-
though the prevalence of intracranial hypertension increases
up to 15-fold with increasing BMI, the risk of intracranial
hypertension is increased even in persons who are only 10%
above ideal body weight (88).
Prevention
Perinatal life: is there a need for preventive strategies in
infancy or even prenatally?
Birth weight, postnatal weight gain, and subsequent obesity. Hu-
man and animal data link the intrauterine environment to
postnatal health, with the underlying mechanisms still un-
known. A U-shaped relationship exists between birth weight
and obesity in young adult life. Low birth weight owing to
maternal undernutrition, smoking, or placental insuffi-
ciency, or alternatively large size at birth attributable most
often to GDM, may both be associated with obesity (89, 90).
Furthermore, the timing of prenatal nutritional deprivation
is apparently important in the future development of obesity,
as discerned in the study of Dutch men exposed to wartime
famine (91). Obesity and ensuing metabolic complications
often persist into middle age. Restricted prenatal growth
with rapid postnatal growth may be key to the early patho-
genesis of adulthood disease. It is likely that genetic factors
in combination with intrauterine programming influence
outcomes (92). As discussed above, breast-feeding is not
unconditionally protective for future obesity, although there
are numerous other benefits.
Proposed suggestions for preventing childhood obesity
beginning in prenatal life and throughout the life cycle at all
levels of society are shown in Table 3.
School-age population
How can we promote a healthy eating environment for children?
Public health strategies to prevent obesity should begin with
schools and extend to the entire community (93). Schools
must review their policies and procedures to promote
healthy eating. This should include review of vending ma-
chine offerings, food available in school cafeterias, and types
of food allowed for classroom events. A curriculum for nu-
trition education to promote healthy eating habits, healthy
body image, and weight management is essential from pre-
school through high school. Healthy eating opportunities
include affordable, palatable fresh fruits and vegetables and
lower-fat food choices in school cafeterias and vending ma-
chines (94, 95). Regulatory agencies should ban advertising
of fast foods directed at preschool children and restrict ad-
vertising to school-age children.
How can we encourage physical activity? Lack of physical ac-
tivity is not limited to inner-city populations but cuts across
socioeconomic, gender, and racial lines (96). A first step
toward increasing activity is to restrict sedentary activities.
Another crucial element for children is to make exercise
readily accessible at all ages in schools and residential areas.
Age-appropriate exercises should be fun, not punitive.
Schools should mandate minimum standards for physical
education, including 30–45 min of strenuous exercise two to
three times weekly.
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Screening
Are screening programs indicated? The justification of any
screening program is to improve important health outcomes
with benefits that will outweigh inconvenience and cost and
direct risks to the subjects. Screening programs for obesity
and its complications would be justified if earlier interven-
tion were shown to reduce morbidity and mortality. Several
systematic reviews have examined the evidence regarding
the benefits, limitations, and cost-effectiveness of a broad
range of clinical preventive services for obesity (97). None of
the published trials has evaluated mass screening, but sur-
rogate measures, i.e. preventive strategies, have been exam-
ined. Firm evidence for the long-term effectiveness of any
single preventive strategy in children is lacking (98). None-
theless, in the opinion of this group, primary care physicians
should screen all children for overweight and obesity. Ide-
ally, where resources permit, children with BMI indicative of
overweight status (i.e. 85th percentile by the U.S. CDC
graphs or 91% by the European-Cole graphs) should
receive weight management counseling, and those with obe-
sity, i.e. BMI at or above the 95th or 99% percentile in the
respective population graphs, should be screened for comor-
bidities discussed above under Causes and Risks and referred
to appropriate specialists if these problems are detected.
Treatment
General considerations
What is the rationale for early intervention? Obese children and
adolescents, like obese adults, are prone to develop many of
the comorbidities outlined above; they also suffer emotional
distress. The vulnerability of the obese child to serious com-
plications makes the case for prevention and treatment ir-
refutable. Still there are some obese children and adults who
appear to suffer few or no metabolic complications (99); the
factors that differentiate such subjects from other obese pa-
tients are currently unknown, and this is a fertile area for
future research.
At what point does excess weight gain justify intervention? Recent
studies of American children and adolescents demonstrate
that fasting serum glucose, insulin, triglycerides, C-reactive
protein, and IL-6 concentrations and the prevalence of im-
paired glucose tolerance and systolic hypertension increase
significantly with increasing obesity (BMI z score  2),
whereas HDL-cholesterol and adiponectin levels decline
(71). Even overweight children (BMI 85–95th percentile) are
at increased risk for dyslipidemia and insulin resistance. In
contrast, rates of dyslipidemia, hypertension, and glucose
intolerance are low among children with BMI less than the
85th percentile for age. Thus, modified diets with decreased
sedentary activities can be justified for children with BMI
between the 85th and 95th percentiles, and more aggressive
treatment should be directed toward children and adoles-
cents with BMI at or above the 95th percentile (or z score 
2) or in less obese children who suffer metabolic, orthopedic,
or cardiopulmonary complications and/or psychological
distress.
At what age should treatment begin? Most of the metabolic
complications of childhood obesity emerge in adolescence
TABLE 3. Proposed suggestions for the prevention of obesity
A. Pregnancy
1. Normalize BMI prior to pregnancy.
2. Do not smoke.
3. Maintain moderate exercise as tolerated.
4. In gestational diabetics, meticulous glucose control.
B. Postpartum and infancy
1. Breast-feeding is preferred for a minimum of 3 months.
2. Postpone introduction of solid foods and sweet liquids.
C. Families
1. Eat meals as a family in a fixed place and time.
2. Do not skip meals, especially breakfast.
3. No TV during meals.
4. Use small plates and keep serving dishes away from the
table.
5. Avoid unnecessary sweet or fatty foods and soft drinks.
6. Remove televisions from children’s bedrooms; restrict times
for TV viewing and video games.
D. Schools
1. Eliminate fundraisers with candy and cookie sales.
2. Review contents of vending machines for healthier choices.
3. Install water fountains.
4. Educate teachers, especially physical education and science
faculty, about basic nutrition and benefits of physical activity.
5. Educate children from preschool through high school on
appropriate diet and lifestyle.
6. Mandate minimum standards for physical education,
including 30–45 min of strenuous exercise two to three times
weekly.
7. Encourage “the walking schoolbus.”
E. Communities
1. Increase family-friendly exercise/play facilities for all age
children.
2. Discourage the use of elevators and moving walkways.
3. Provide information on how to shop and prepare healthier
versions of cultural-specific foods.
F. Healthcare providers
1. Explain biological and genetic noncontrollable contributions
to obesity.
2. Give age-appropriate expectations for body weight in
children.
3. Work toward classifying obesity as a disease to promote
recognition, reimbursement for care, and willingness and
ability to provide treatment.
G. Industry
1. Mandate age-appropriate nutrition labeling for products
aimed at children (e.g., red-light/green-light foods, with
portion sizes).
2. Encourage marketing of interactive video games in which
children must exercise in order to play.
3. Use celebrity advertising directed at children for healthful
foods to promote breakfast and regular meals.
H. Government and regulatory agencies
1. Classify obesity as a legitimate disease.
2. Find novel ways to fund healthy lifestyle programs, i.e. with
revenues from food/drink taxes.
3. Subsidize government-sponsored programs to promote
consumption of fresh fruits and vegetables.
4. Provide financial incentives to industry to develop more
healthful products and to educate the consumer on product
content.
5. Provide financial incentives to schools that initiate innovative
physical activity and nutrition programs.
6. Allow tax deductions for the cost of weight loss and exercise
programs.
7. Provide urban planners with funding to establish bicycle,
jogging, and walking paths.
8. Ban advertising of fast foods directed at preschool children,
and restrict advertising to school-age children.
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and young adulthood. However, five lines of evidence re-
viewed above suggest that intervention is warranted, even in
obese children. First, severe obesity in toddlers and young
children is frequently accompanied by sleep apnea (82) and
orthopedic anomalies (Blount’s disease) (86). Second, some
obese children develop glucose intolerance, T2DM, dyslip-
idemia, and hypertension even before the onset of puberty
(71). Third, excessive weight gain between the ages of 2 and
10 yr increases the risks of adult obesity and glucose intol-
erance, especially when the parents are obese and/or have
diabetes (12). Fourth, early vascular lesions have been de-
tected in obese children as young as 3–8 yr of age, suggesting
strongly that obesity-related atherogenesis begins in child-
hood (78). Finally, intervention to prevent or reverse obesity
in its early stages perhaps may be more successful and ben-
eficial than treatment of established, severe obesity in ado-
lescence or adulthood.
What are the goals of treatment? Goal setting and treatment of
pediatric patients, many of whom are still growing, must be
individualized. The first goal is to restore the balance be-
tween energy intake and energy expenditure; in cases in
which intake is clearly excessive, it will be necessary to re-
strict calories while increasing energy expenditure.
Stabilization of weight in growing children decreases BMI
z score slowly. Nevertheless, studies in adults suggest that
a 5–10% reduction in body weight at a rate of 0.5 kg/wk and
maintained over a period of 2–5 yr may increase insulin
sensitivity and improve glucose tolerance (100) among other
salutary changes. Thus, obese children (and their physicians)
should be encouraged by any reduction in BMI z score. The
long-term objectives of treatment of childhood obesity are to
reduce BMI z score to less than 2 and reverse and prevent
short- and long-term comorbidities.
Lifestyle
Which treatment approach should be used first?
General considerations. The benefits of lifestyle intervention
are most likely to be achieved when diet and exercise pro-
grams are coordinated with individual and family counsel-
ing and behavior modification (101). Long-term success re-
quires continuous implementation; experience in adults
indicates that discontinuation of any therapeutic approach
leads to rebound weight gain in the great majority of subjects.
Eating disorders and other psychiatric disorders are common
in obese subjects and must be addressed; otherwise, thera-
peutic failure is assured.
Parents provide a child’s contextual environment and thus
should be considered key players in interventions aimed at
preventing or treating weight-related problems. Parenting
style and feeding style are crucial factors in fostering healthy
lifestyle and awareness of internal hunger and satiety cues
and deemphasizing thinness (102). In most family-based be-
havioral weight-loss programs for children, the obese child
is the main target of change with varying degrees of parental
involvement (103). Interestingly, recent reports suggest
greater weight loss in obese children when parents alone are
targeted for intervention (104). These data suggest that the
stigma of obesity treatment per se may be counterproductive
in this age group.
Dietary approaches. Mild caloric restriction is safe and can
be effective when obese children and their families are mo-
tivated and encouraged to change longstanding feeding be-
haviors. An example of such a program aimed at families
with children is the traffic light diet (105). Significant reduc-
tions in weight are unusual and often transient unless caloric
restriction is accompanied by increased energy expenditure.
Diets severely restricted in calories, including high-protein,
very low-calorie diets, can facilitate more dramatic short-
term weight loss. However, such diets cannot be sustained
under free-living conditions (106) and are potentially dan-
gerous. Severe caloric restriction may cause deficiencies of
vitamins, minerals, and critical micronutrients; limit bone
accretion and mineralization; reduce rates of linear growth;
and disrupt menstrual cycles (107).
The role of specific dietary macronutrients in the patho-
genesis and treatment of obesity is highly controversial. A
low-fat diet in combination with exercise and weight loss can
reduce significantly the risks of T2DM and cardiovascular
disease in adults with impaired glucose tolerance. Yet recent
investigations showed that obese men and women lost more
weight and had more significant reductions in plasma tri-
glyceride concentrations on low-carbohydrate diets than on
conventional low-fat diets (108). A 3-month study in over-
weight adolescents found similar effects (mean decrease in
weight 9.9 kg in the low-carbohydrate group vs. 4.9 kg in the
low-fat group); low-density lipoprotein (LDL) levels de-
clined with the low-fat diet but not with the low-carbohy-
drate diet (109). A review of adult studies suggests that the
efficacy of low-carbohydrate diets may be related to overall
caloric restriction rather than reduction in carbohydrate in-
take per se. Moreover, the benefits of low-carbohydrate diets
may diminish with time (110).
Limited evidence suggests that the nature or quality of
ingested carbohydrate may modulate childhood weight
gain. The insulin secretory response to foods containing rap-
idly absorbed, concentrated carbohydrates (high glycemic
index) exceeds the response to foods containing high con-
centrations of protein, fat, and fiber. Studies of the effects of
glycemic index on weight gain in children are inconclusive.
Still, observations among adolescents have found that con-
sumption of sugar-sweetened drinks is an independent vari-
able associated with increasing BMI (53, 111). In a separate
study, a modified low-glycemic diet (45–50% carbohydrate,
30–35% fat) reduced BMI (1.3 vs. 0.7 with a low-fat diet) and
fat mass in obese adolescents (112). Thus, it appears that
elimination of carbonated drinks or other sugary drinks
(juice and sports drinks) from the diet can significantly re-
duce caloric intake and obesity (113).
Other macronutrients, vitamins, and trace elements may
modulate the risk of metabolic complications. For example,
intake of fiber (particularly whole grains and cereal) corre-
lates inversely with the risks of T2DM and cardiovascular
disease (114). Insoluble and soluble fibers limit macronutri-
ent absorption and thereby increase fat oxidation and im-
prove glucose tolerance. The intake of magnesium (from
whole grains, nuts, and green leafy vegetables) and dairy
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products containing vitamin D and calcium may also cor-
relate inversely with the risks of obesity and T2DM in chil-
dren and young adults (115).
Exercise. A sedentary lifestyle increases the risks of child-
hood obesity and predisposes to diabetes and cardiovascular
disease, whereas exercise, in combination with caloric and fat
restriction, reduces the rate of progression to diabetes in
adults with impaired glucose tolerance and limits cardio-
vascular morbidity and mortality. The benefits of exercise are
mediated, at least in part, by reductions in total and visceral
fat stores and increases in lean body mass, which augment
resting energy expenditure (116). Exercise enhances adipose
tissue sensitivity to insulin; reduces fasting and postprandial
free fatty acid, LDL, and triglyceride concentrations; and
increases plasma HDL levels. The heightened sensitivity to
insulin and induction of fatty acid oxidation enhance vas-
cular endothelial function (117).
Available evidence, albeit limited, suggests that exercise
can benefit obese children and reduce the risks of metabolic
and cardiovascular complications. A randomized, modified
cross-over study of 79 obese children (aged 7–11 yr) dem-
onstrated that 4 months of exercise training (40 min of ac-
tivity 5 d/wk) reduced percent body fat (5%) and decreased
fasting insulin (10%) and triglyceride (17%) concentrations,
even in the absence of dietary intervention (118). Additional
uncontrolled trials suggest that aerobic exercise can also im-
prove vascular endothelial function (119). The benefits of
exercise are quenched or reversed rapidly if activity is not
maintained.
The capacity for voluntary exercise declines as BMI rises.
It is therefore critical to begin regular exercise before the child
becomes morbidly obese and functionally immobile. A sum-
mary of proposed suggestions for basic lifestyle intervention
in children is provided in Table 4. The Cochrane study con-
cluded that “there are limited high-quality data on the ef-
fectiveness of obesity prevention programs, and no gener-
alizable conclusions can be drawn. However, concentration
on strategies that encourage reduction in sedentary behav-
iors and increase in physical activity may be fruitful” (98).
Thus, lack of formal evidence does not preclude action.
Diet and exercise regimens may prove effective for short-
term treatment of pediatric obesity. However, the long-term
success of lifestyle intervention alone has been disappoint-
ing. For example, in an Italian multicenter study of nutri-
tional intervention in 1383 obese pediatric patients, drop-out
rates ranged from 30–34% after 3 months to 90–94% after 2
yr (120). Noncompliance was highest in the most obese chil-
dren. A Cochrane review of randomized, controlled trials of
duration 6 months or more (n  18 studies, 975 participants)
concluded that most studies are too small to detect effects of
treatment, and few trials use the same comparisons and
outcomes (103). Thus, the data are of limited quality.
Pharmacotherapy
If supervised lifestyle intervention fails, the patient should
be referred to a subspecialist for evaluation. The subspecialist
should assess the extent and magnitude of comorbidities and
may consider more intensive therapeutic approaches includ-
ing pharmacotherapy. Current pharmacologic interventions
are designed to increase energy expenditure (stimulants),
suppress caloric intake (anorectic agents), limit nutrient ab-
sorption and/or modulate insulin production and/or action.
Stimulants. The use of metabolic stimulants for the treatment
of obesity has a checkered history. Many antiobesity drugs
once considered safe and effective, i.e. thyroid hormone,
dinitrophenol, amphetamine, fenfluramine, dexfenflura-
mine, phenylpropanolamine, and ephedra, have been aban-
doned because they caused dangerous and in some cases
life-threatening complications.
A single short-term trial compared caffeine plus ephedrine
with placebo in adolescents taking a mildly hypocaloric diet.
Although the drug-treated subjects lost more weight, ad-
verse effects were more frequent (121). These agents cannot
be recommended.
Anorectic agents. The only anorectic agent currently approved
for use in obese adolescents (older than 16 yr) is sibutramine,
a nonselective inhibitor of neuronal reuptake of serotonin,
norepinephrine, and dopamine. In combination with caloric
restriction and a comprehensive family-based behavioral
program, sibutramine reduced BMI 8.5  6.8% in 43 obese
adolescents during an initial 6-month period; a 4.0  5.4%
reduction in BMI was achieved in 39 placebo-treated subjects
(122). No additional weight loss occurred during a subse-
quent 6 months of therapy. Fasting insulin concentrations
declined and HDL levels increased. However, 19 of 43 sub-
jects treated with sibutramine developed mild hypertension
and tachycardia, necessitating reduction in drug dose, and
five had sustained elevations in blood pressure that required
discontinuation of the drug. Other potentially serious com-
plications include insomnia, anxiety, headache, and depres-
sion. There is a heightened risk of the serotonin syndrome if
sibutramine is used in combination with monoamine oxidase
inhibitors, buspirone, lithium, or meperidine, or selective
serotonin reuptake inhibitors, such as fluoxetine, triptans,
dextromethorphan, ergot alkaloids, or fentanyl.
Anorectic agents should complement, never replace, a diet
and exercise program. The drugs have modest effects on total
body weight (typically an additional 2–10 kg in obese adults),
and responses vary considerably among individuals. Most of
the weight loss from anorectic agents is achieved within the
TABLE 4. Basic treatment interventions: lifestyle changes
Dietary suggestions
1. Eliminate all sugary drinks (including juice), and replace
with water, noncaloric beverages, and lowfat or skim milk.
2. Restrict calories enough to produce mild negative energy
balance.
3. Reduce intake of saturated fats, salty snacks, and high
glycemic foods including candy, white bread, white rice,
pasta, and potatoes.
4. Create a balanced diet containing vegetables, fruits, whole
grains, nuts, fiber, lean meat, fish and low-fat dairy products.
Exercise suggestions
1. Exercise should be fun, age-specific, and tailored to the child’s
fitness level and ability.
2. Involve large muscle groups to increase energy expenditure.
3. Increase frequency, intensity, and duration with time.
4. Restrict sedentary behaviors: television viewing, video games,
and internet “surfing.”
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first 4–6 months of treatment due to the achievement of a
negative plateau; regain of weight is the norm unless drug
therapy is maintained. Administration of this drug is not
recommended for more than 2 yr duration.
Leptin treatment has been given to children with genetic
leptin deficiency resulting in dramatic weight reduction (26),
but it is doubtful that individuals with nonleptin-deficient
forms of obesity will benefit from similar treatment.
Drugs that limit nutrient absorption. The drug orlistat inhibits
pancreatic lipase and thereby increases fecal losses of tri-
glyceride. Orlistat decreases body weight and total and LDL
cholesterol levels and reduces the risk of T2DM in adults
with impaired glucose tolerance. In the United States, orlistat
is currently approved by the Food and Drug Administration
in children older than 12 yr. In obese adolescents, the com-
bination of orlistat with lifestyle intervention reduced weight
(4.4  4.6 kg), BMI (1.9  2.5 kg/m2), total cholesterol
(21.3  24.7 mg/dl or 0.55  0.64 mmol/liter), LDL
(17.3  15.8 mg/dl or 0.45  0.41 mmol/liter), fasting
insulin (13.7  19.0 U/ml or 95.1  132.0 pmol/liter), and
fasting glucose (15.4  7.4 mg/dl or 0.85  0.41 mmol/
liter) concentrations and increased insulin sensitivity during
a 3-month trial period (123). There was considerable vari-
ability in response to the drug. Variable reductions in body
weight (12.7  2.5 kg) and fat mass were also noted in a
study of 11 morbidly obese children aged 7–12 yr. Side effects
are tolerable as long as subjects reduce fat intake, but vitamin
A, D, and E levels may decline despite multivitamin sup-
plementation. High study dropout rates (25% or more) sug-
gest that long-term fat restriction is problematic in teenagers;
dietary noncompliance results in flatulence and diarrhea that
ultimately prove unacceptable.
Insulin sensitizers and suppressors. The synthesis and storage
of triglyceride in adipose tissue are stimulated by insulin.
Thus, increases in nutrient-dependent insulin production
and/or fasting hyperinsulinemia may contribute to fat stor-
age and limit fat mobilization. By reducing fasting or post-
prandial insulin concentrations, certain pharmacologic
agents may prove beneficial in the treatment of obese chil-
dren and adults. In this drug class, only metformin treatment
results in weight loss.
Metformin. Metformin is a bisubstituted, short-chain hydro-
philic guanidine derivative that activates AMP protein ki-
nase. Its major site of action is the liver: the drug increases
hepatic glucose uptake, decreases gluconeogenesis, and re-
duces hepatic glucose production. Major advantages of the
drug include decreased food intake, weight loss, decreased
fat stores (sc more than visceral), improved lipid profiles, and
a reduction in conversion to T2DM among adults with im-
paired glucose tolerance.
There have been two randomized, double-blind, placebo-
controlled studies of metformin in obese adolescents with
insulin resistance, normal glucose tolerance, and a positive
family history of type 2 diabetes. In the first trial (n  29),
metformin reduced BMI z score (3.6% relative to placebo
controls), plasma leptin, and fasting glucose (9.8 mg/dl or
0.54 mmol/liter) and insulin (12 U/ml or 83.3 pmol/
liter), even in the absence of dietary intervention (124). In the
second trial (n  24), in conjunction with a low-calorie diet,
metformin reduced weight 2.7% relative to controls and de-
creased plasma leptin, insulin, glucose, cholesterol, and tri-
glyceride concentrations (125).
Metformin is generally well tolerated, although many pa-
tients have transient abdominal discomfort, avoidable by taking
the medication with food. Lactic acidosis is extraordinarily rare
in pediatric patients, but metformin should not be administered
to children with underlying cardiac, hepatic, renal, or gastro-
intestinal disease. Obese subjects with mild elevations in he-
patic enzymes (less than 3-fold higher than established norms)
may receive the drug; indeed, some studies suggest that met-
formin may be useful in treatment of hepatic steatosis. Con-
current use of a multivitamin is warranted because metformin
increases urinary excretion of vitamins B1 and B6. Metformin is
approved by the Food and Drug Administration for treatment
of T2DM but not currently for treatment of childhood obesity
or insulin resistance.
Octreotide. Octreotide binds to the somatostatin-5 receptor
and thereby impairs closure of the -cell calcium channel,
reducing glucose-dependent insulin secretion. In a double-
blind, placebo-controlled trial in children with hypothalamic
obesity, octreotide reduced insulin secretory responses and
rates of weight gain (1.6  0.6 vs. 9.2  1.5 kg) and BMI
(0.2  0.2 vs. 2.3  0.5 kg/m2) (126). The cost of the
medication, the need for parenteral administration, and the
drug’s side effects, which may include transient gastrointes-
tinal distress, gallstones, suppression of GH and TSH secre-
tion, and cardiac dysfunction, limit its current applicability
to patients with intractable obesity from hypothalamic
injury.
Bariatric surgery
The long-term success of lifestyle intervention and pharma-
cotherapy in subjects with severe obesity has in general been
disappointing. Marked weight loss is highly unusual and rarely
sustained, and metabolic and vascular complications are com-
mon, albeit not universal. More aggressive approaches such as
bariatric surgery may be indicated in selected subjects with
extreme obesity and serious comorbidities. The surgical ap-
proaches now used most commonly are the laparoscopic gastric
banding procedure and the Roux-en-Y gastric bypass (RYGB).
Gastric banding may cause esophageal dilatation and
achalasia and may exacerbate gastroesophageal reflux. Other
potential complications include port site malposition or mal-
function, balloon rupture, and infection. Complications of
RYGB include iron-deficiency anemia (50%); folate, thia-
mine, or calcium deficiencies (at least 30%); cholecystitis
(20%); wound infections and dehiscence (10%); small bowel
or stomach obstruction (5–10%); atelectasis and pneumonia
(12%); and incisional hernia (10%). Prophylactic tracheos-
tomy may be required to maintain airway patency and cor-
rect preoperative hypercapnia. Other possible complications
include leaks at the anastomotic junction, gastric dilatation,
and dumping syndrome. Among the most serious compli-
cations are potentially fatal pulmonary emboli. Mortality
rates for RYGB range from 1 to 5%. Complication rates may
be reduced if bariatric procedures are performed through
laparoscopy by an experienced surgeon. There have been
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relatively few published surgical trials pertaining to adoles-
cents (127, 128); however, the outcomes seem to parallel
bariatric surgery performed in adults (129) and warrant fur-
ther investigation (130).
Care coordination
How should the clinician balance lifestyle intervention, pharma-
cotherapy, and surgery in the treatment of obesity? Lifestyle
intervention is indicated for all overweight and obese chil-
dren and should be maintained, even if more aggressive/
intensive measures are adopted.
Pharmacotherapy may be considered for complicated obe-
sity in peripubertal children or adolescents who fail to re-
spond to at least a 6-month trial of supervised lifestyle in-
tervention despite good faith effort. The term complicated
obesity implies the presence of major comorbidities includ-
ing glucose intolerance, hypertension, dyslipidemia, sleep
apnea, or other comorbidities discussed above. Failure to
respond means that the comorbidities persist or worsen de-
spite lifestyle intervention. Good faith effort means the pa-
tient has attempted to follow dietary recommendations and
has increased energy expenditure through regular exercise.
Given its efficacy in treating obese, insulin-resistant ado-
lescents, its track record of safety, and its ability to limit food
intake and weight gain, the authors consider metformin the
drug of choice for treating the obese adolescent with severe
insulin resistance or glucose intolerance.
Anorectic agents such as sibutramine should not be ad-
ministered to prepubertal children. Use of this drug in any-
one under age 16 yr remains experimental and should be
undertaken only in specialized pediatric treatment centers in
the context of clinical trials approved by institutional review
boards. Neuropsychologic testing before and during therapy
may be warranted. Inhibitors of nutrient absorption such as
orlistat are not tolerated by many obese children but might
be applied successfully in selected, highly motivated pa-
tients. The use of octreotide for treatment of hypothalamic
obesity, although promising, remains experimental. Other
medications are in phase III studies in obese adults (reviewed
in Ref. 131) but will not be available for children for several
years.
Firm or uniform guidelines regarding duration of phar-
macologic treatment are not feasible at this time. A trial off
medication may be warranted if comorbidities are reversed,
particularly if there has been a significant decline in BMI z
score. In all cases, pharmacotherapy should be discontinued
if the patient fails to respond to the drug.
Bariatric surgery should be reserved for treatment of ad-
olescents with extreme obesity (usually defined as BMI  40
or  35 with established comorbidities) who have failed
other treatment approaches. Surgery should be performed
only under the rubric of clinical trials in medical centers that
have expertise in bariatric surgical techniques and are sup-
ported by multidisciplinary teams with long-standing expe-
rience in the evaluation and management of obese children.
Contraindications to bariatric surgery include substance
abuse or psychiatric disabilities (including severe eating dis-
orders) that prevent lifelong compliance with nutritional
recommendations or medical surveillance (127, 128).
Who should receive intensive evaluation and treatment? In most
cases, the primary care physician will be responsible for
management of overweight infants and children. Clearly the
burden is too large to be borne by specialty physicians. It is
very important for primary care physicians to recognize in-
dividual overweight patients and intervene before they be-
come obese (132). Basic dietary advice should be provided in
the primary care setting. This should include elimination of
all sweetened beverages, including juices, caloric carbonated
drinks, iced tea, and lemonade; use of low-fat or fat-free milk
in children over the age of 2 yr; portion control; increased
fruit and vegetable intake; reduction in fast food consump-
tion; and counseling about the need for daily vigorous ex-
ercise. Weekly office weigh-ins can monitor home progress,
and if this is deemed insufficient, the child should be seen by
a registered dietitian or enrolled in a formal weight-man-
agement program. Patients who have unusual distinguish-
ing characteristics may require a specialist’s consultation.
There are several examples of these characteristics. First,
infants who have rapid weight gain and abnormally low
linear growth are likely to have an underlying disease. In
addition, infants with syndromic features, neurological def-
icits, or abnormal fat distribution associated with obesity
require further expert evaluation.
In addition, children and adolescents who meet the criteria
for obesity (BMI  95%) and those with eating disorders
should be referred for expert evaluation and intervention.
Children with an early age of adiposity rebound (the period
when the BMI begins to increase after reaching a nadir in
early childhood) are at highest risk for overweight, later
glucose intolerance, and diabetes (133). These children also
need a thorough clinical evaluation.
As genotype-phenotype knowledge increases, lifestyle,
pharmacologic, and surgical therapies may be applied more
rationally to specific individuals.
Where should delivery of advanced care be centered? Obese pa-
tients with comorbidities such as sleep apnea, glucose intoler-
ance, hypertension, nonalcoholic steatohepatitis, polycystic
ovarian syndrome, and dyslipidemia will require the expertise
of subspecialists in pediatric endocrinology, gastroenterology,
nutrition, cardiology, exercise and sports medicine, pulmonary
medicine, orthopedics, and behavioral medicine; their efforts
must be coordinated within the setting of specialized obesity
clinics. Until a safe and effective treatment can be recommended
for severely obese children, intensive inpatient treatment ap-
proaches should remain an option in specialized centers for
limited durations in the context of a comprehensive, long-term
management program. The intensive therapies that have been
used to treat pediatric and adolescent obesity include very
low-calorie diets, pharmacotherapy, and bariatric surgery. Psy-
chosomatic units specializing in the treatment of eating disor-
ders are the logical choice by providing a milieu for the obese
children and adolescents with life-threatening medical compli-
cations. Such programs adhere to recommendations of the Ex-
pert Committee on Obesity Evaluation and Treatment for an
effective behavioral and nutritional approach for child obesity
(134). These include a group format with individualized be-
havioral counseling, intensive family involvement and training,
behavior modification targeted at changing home and family
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lifestyle, moderated caloric restriction targeted at inducing
modest (5–10%) weight reduction associated with improve-
ment of medical complications, a physical activity program
emphasizing choice and reinforcing reduced sedentary behav-
iors, skills for managing high-risk situations, and skills for
maintenance and relapse prevention.
Conclusions
In the foregoing pages, we have described the problems
associated with childhood obesity, providing strong evi-
dence that adult morbidities may begin in early life. Perhaps
because of the rapid evolution of these problems, public
policy makers have not yet taken action to address existing
and future repercussions. Obesity is now a major contribut-
ing factor to increasing rates of disability among adults (135).
Health care costs of patients with a BMI greater than 35 are
approximately 44% more than those of nonobese patients.
Furthermore, it is well established that the health care costs
of treating patients with T2DM, a common sequel of obesity,
are substantially higher than treatment for patients without
diabetes. This should provide incentive for the private and
public sectors to: 1) mobilize all available resources to stem
the tide of increasing body mass in children and adults, 2)
classify obesity as a disease, paving the way for public fund-
ing and ensurers’ reimbursement for obesity treatment pro-
grams, and 3) spur further research to more effectively pre-
vent and treat obesity. Precedents for successful public
health campaigns include those designed to stem tobacco
use, prevent the spread of HIV, and promote the use seat
belts in motor vehicles and bicycle helmets in children. Pro-
fessional societies (especially those dedicated to primary care
and endocrinology), health care providers, and educators
should assume leadership roles in achieving these goals (23).
The WHO has formulated a plan to tackle obesity, and the
IOTF has created a credentialing system for obesity special-
ists and treatment centers. In the United States, the Depart-
ment of Health and Human Services recently convened an
Obesity Summit to discuss the best means of addressing this
critical public health problem. These are laudable milestones,
which we hope will make inroads into ameliorating the crisis.
Measures to prevent childhood obesity are listed in Table
3, and basic lifestyle interventions are summarized in Table
4. An overall summary of this consensus development con-
ference is presented in Table 5. These aspects must be em-
phasized as the safest means for primary care physicians to
manage patients. The decision of when to intervene with
pharmacotherapy or bariatric surgery must be made for chil-
dren and adolescents on a case-by-case basis, according to the
guidelines presented above. To date, although somewhat
encouraging, only limited and short-term evidence is avail-
able to support the use of selected drugs or surgical proce-
dures to alleviate morbid obesity in this population. Longer-
term clinical trials with larger numbers of children and
adolescents will be required before drug treatment or sur-
gical intervention can be routinely employed.
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